What is ImmunoPrecise Antibodies Ltd.'s share price today?
ImmunoPrecise Antibodies Ltd. (HYFT) share price today is $1.15 as of October 27, 2026 at 1:29 AM IST. The stock touched a day high of $1.20 and a day low of $1.11.What exchange does ImmunoPrecise Antibodies Ltd. stock trade on, and under what ticker symbol?
ImmunoPrecise Antibodies Ltd. stock trades on NASDAQ under the ticker symbol HYFT.What is ImmunoPrecise Antibodies Ltd.'s market capitalization?
ImmunoPrecise Antibodies Ltd.'s market capitalization is $54.64M as of October 27, 2026 at 1:29 AM IST.What is ImmunoPrecise Antibodies Ltd.'s price-to-earnings (P/E) ratio?
ImmunoPrecise Antibodies Ltd.'s price-to-earnings (P/E) ratio is N/A as of October 26, 2026.What is ImmunoPrecise Antibodies Ltd.'s price-to-book (P/B) ratio?
ImmunoPrecise Antibodies Ltd.'s price-to-book (P/B) ratio is 13.97 as of October 26, 2026.Can Indian investors buy ImmunoPrecise Antibodies Ltd. shares?
Yes, You can buy ImmunoPrecise Antibodies Ltd. shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.How can I invest in ImmunoPrecise Antibodies Ltd. shares from India?
Indian investors can buy ImmunoPrecise Antibodies Ltd. shares in three steps: 1. Search ImmunoPrecise Antibodies Ltd. on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.How does USD-INR currency movement affect returns from ImmunoPrecise Antibodies Ltd. shares for Indian investors?
Since ImmunoPrecise Antibodies Ltd. trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.What is the minimum amount required to invest in ImmunoPrecise Antibodies Ltd. shares via Tickertape?
Indian investors can start investing in ImmunoPrecise Antibodies Ltd. (HYFT) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 8.658 shares at the current price of $1.15.
$
₹
$1.150.43% (-0.00)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
Key Metrics
Key Metrics
PE TTM
PE TTM
Close price divided by the earnings per share for the trailing twelve months
—
PB
PB
Close price divided by the book value per share at the end of the most recent quarter
13.97
EPS TTM
EPS TTM
Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)
$-0.24
PEG Ratio
PEG Ratio
Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years
—
Profit Margin
Profit Margin
Net profit divided by the total revenue for the most recent financial year
-105.2%
Dividend Yield
Dividend Yield
Annual dividend per share for the trailing twelve months divided by the close price
—
Based on 3 analysts reports
Buy3 analysts
Hold0 analyst
Sell0 analyst
Price Upside
+273.56%
Earnings Growth
-12.81%
Rev. Growth
+14.62%
Company Profile
Company Profile
P/E Ratio
21.63
21.63
1Y Return
10.54%
10.54%
Buy Reco %
48.00
48.00
P/E Ratio
18.39
18.39
1Y Return
3.57%
3.57%
Buy Reco %
37.03
37.03
P/E Ratio
15.16
15.16
1Y Return
4.14%
4.14%
Buy Reco %
44.82
44.82
GIB
P/E Ratio
14.08
14.08
1Y Return
6.99%
6.99%
Buy Reco %
53.33
53.33
P/E Ratio
20.82
20.82
1Y Return
8.22%
8.22%
Buy Reco %
20.00
20.00
Forecast
Forecast
Price
Revenue
Earnings
Price Forecast
Price Forecast
2026
Current$1.16Baseline
Analyst Target - 1 year
Target$4.33+273.56%
All values in $
2026
Current$1.16Baseline
Analyst Target - 1 year
Target$4.33+273.56%
All values in $
Revenue Forecast
Revenue Forecast
Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.
The next fiscal year's mean estimate implies 14.62% growth, versus a trailing 3-year CAGR of -9.50%.
2026
Current$15.31Baseline
Forecast for Apr 2027
High$18.83+22.94%
Average$17.55+14.62%
Low$16.5+7.71%
All values in $ Million
2026
Current$15.31Baseline
Forecast for Apr 2027
High$18.83+22.94%
Average$17.55+14.62%
Low$16.5+7.71%
All values in $ Million
Earnings Per Share Forecast
Earnings Per Share Forecast
2026
Current$-0.26Baseline
Forecast for Apr 2027
High$-0.28-7.69%
Average$-0.29-12.81%
Low$-0.32-21.54%
All values in $
2026
Current$-0.26Baseline
Forecast for Apr 2027
High$-0.28-7.69%
Average$-0.29-12.81%
Low$-0.32-21.54%
All values in $
Financials
Financials
Income
Balance Sheet
Cash Flow
Quarterly Normal View
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Revenue
Net Income
| Financial Year | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 6.45 | 2.47 | 2.67 | 6.15 | 6.98 | 3.16 | 4.12 | 4.09 | 4.07 | 3.89 |
Gross Profit | 3.10 | 1.01 | 1.36 | 3.29 | 4.46 | 1.52 | 2.66 | 2.42 | 2.47 | 2.28 |
| Net Income | -18.04 | -3.99 | -2.55 | -21.52 | -2.16 | -2.95 | -3.19 | -3.86 | -3.83 | -6.18 |
| Net Profit Margin | -279.37% | -161.70% | -95.29% | -349.87% | -30.95% | -93.60% | -77.47% | -94.51% | -93.92% | -158.71% |
Peers
Peers & Comparison
Peers & Comparison
Comparing 2 stocks from
HealthcareBiotechnology
HealthcareBiotechnology
Valuation
Returns
Forecast
Compare valuation on Screener| Stock | PE TTMPE TTM | PBPB | PEG RatioPEG Ratio |
|---|---|---|---|
| ImmunoPrecise Antibodies Ltd. | - | 13.97 | - |
| International Business Machines | 21.63 | 6.32 | 2.18 |
| Accenture plc | 18.39 | 4.87 | 1.89 |
Price Comparison
Price Comparison
Compare HYFT with any stock or ETFCompare HYFT with any stock or ETF
Comparing from
HYFT
IBM
ACN
The 12-month consensus target implies 273.56% growth, versus a trailing 3-year CAGR of -1.67%.